Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza A (H1N1) 2009 monovalent vaccine live
- Development stage
- Approved
- Lead developer
- MedImmune
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
The influenza A (H1N1) 2009 monovalent vaccine live is a live-attenuated influenza vaccine (LAIV) specifically developed to prevent infection from the pandemic A/California/7/2009 (H1N1) virus. Developed by MedImmune (a subsidiary of AstraZeneca), this vaccine is administered via an intranasal spray and utilizes a cold-adapted, temperature-sensitive master donor virus. This platform allows the vaccine virus to replicate in the cooler environment of the nasopharynx but restricts its growth in the warmer lower respiratory tract, thereby inducing a protective immune response without causing systemic disease. The vaccine elicits both mucosal immunity through IgA production and systemic immunity via T-cell and B-cell activation, mimicking a natural infection. It was authorized for use in individuals aged 2 through 49 years during the 2009 pandemic before the strain was eventually incorporated into seasonal multi-strain vaccines.
- Brand names
- Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal
- Other names
- H1N1 (2009) LAIV2009 pandemic H1N1 live attenuated influenza vaccinemonovalent live attenuated influenza vaccineH1N1 live vaccineH-1N1 live vaccineH 1N1 live vaccine
02
Targets
Sialoglycan (Cell-surface sialoglycan)
Beyond the preview
Go deeper on influenza A (H1N1) 2009 monovalent vaccine live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza A (H1N1) 2009 monovalent vaccine live.